Literature DB >> 25623737

Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment.

Philip M Hanno1, Deborah Erickson1, Robert Moldwin1, Martha M Faraday1.   

Abstract

PURPOSE: The purpose of this amendment is to provide an updated clinical framework for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome based upon data received since the publication of original guideline in 2011.
MATERIALS AND METHODS: A systematic literature review using the MEDLINE(®) database (search dates 1/1/83-7/22/09) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of IC/BPS. This initial review yielded an evidence base of 86 treatment articles after application of inclusion/exclusion criteria. The AUA update literature review process, in which an additional systematic review is conducted periodically to maintain guideline currency with newly published relevant literature, was conducted in July 2013. This review identified an additional 31 articles, which were added to the evidence base of this Guideline.
RESULTS: Newly incorporated literature describing the treatment of IC/BPS was integrated into the Guideline with additional treatment information provided as Clinical Principles and Expert Opinions when insufficient evidence existed. The diagnostic portion of the Guideline remains unchanged from the original publication and is still based on Expert Opinions and Clinical Principles.
CONCLUSIONS: The management of IC/BPS continues to evolve as can be seen by an expanding literature on the topic. This document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient. As the science relevant to IC/BPS evolves and improves, the strategies presented will require amendment to remain consistent with the highest standards of care.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cystitis; interstitial; lower urinary tract symptoms; pelvic pain; urinary bladder diseases; urodynamics

Mesh:

Year:  2015        PMID: 25623737     DOI: 10.1016/j.juro.2015.01.086

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  179 in total

1.  Evaluation of several botulinum toxins-A delivering systems into the bladder in interstitial cystitis/painful bladder syndrome (IC/PBS).

Authors:  Farbod Torkamand; Seyed Javad Mirjavadi; Fatemeh Khatami; Fateme Guitynavard; Seyed Mohammad Kazem Aghamir
Journal:  Am J Clin Exp Urol       Date:  2019-10-25

2.  Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial.

Authors:  Kristina Cvach; Anna Rosamilia; Peter Dwyer; Yik Lim; Alison DeSouza; Linli Ow; Elizabeth Thomas; Christine Murray; Alison Leitch; Lore Schierlitz
Journal:  Int Urogynecol J       Date:  2021-01-16       Impact factor: 2.894

Review 3.  Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Aram Kim; Dong-Myung Shin; Myung-Soo Choo
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

4.  Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study.

Authors:  Shilpa Iyer; Elizabeth Lotsof; Ying Zhou; Alexis Tran; Carolyn Botros; Peter Sand; Roger Goldberg; Janet Tomezsko; Adam Gafni-Kane; Sylvia Botros
Journal:  Int Urogynecol J       Date:  2017-02-01       Impact factor: 2.894

5.  Sensory mapping of pelvic dermatomes in women with interstitial cystitis/bladder pain syndrome.

Authors:  Tatiana Sanses; Patrick McCabe; Ling Zhong; Aisha Taylor; Gisela Chelimsky; Sangeeta Mahajan; Tony Buffington; Adonis Hijaz; Sarah Ialacci; Jeffrey Janata; Thomas Chelimsky
Journal:  Neurourol Urodyn       Date:  2017-06-19       Impact factor: 2.696

Review 6.  Stimulators and activators of soluble guanylate cyclase for urogenital disorders.

Authors:  Fabiola Z Mónica; Edson Antunes
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

7.  Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome.

Authors:  Yik N Lim; Peter Dwyer; Christine Murray; Debjyoti Karmakar; Anna Rosamilia; Elizabeth Thomas
Journal:  Int Urogynecol J       Date:  2016-12-16       Impact factor: 2.894

Review 8.  Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives.

Authors:  Yoshiyuki Akiyama; Yi Luo; Philip M Hanno; Daichi Maeda; Yukio Homma
Journal:  Int J Urol       Date:  2020-04-04       Impact factor: 3.369

9.  Sensory pudendal nerve stimulation increases bladder capacity through sympathetic mechanisms in cyclophosphamide-induced cystitis rats.

Authors:  Eric J Gonzalez; Warren M Grill
Journal:  Neurourol Urodyn       Date:  2018-10-23       Impact factor: 2.696

10.  Understanding bladder pain syndrome/interstitial cystitis.

Authors:  Visha Tailor; Marco Torella; Valentin Manriquez; Giuseppe Alessandro Digesu
Journal:  Int Urogynecol J       Date:  2020-08       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.